We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-9 of 9

Judgment of the European Court of Justice in the GSK dual pricing case

  • Bird & Bird
  • -
  • European Union
  • -
  • October 13 2009

The European Court of Justice ("ECJ") has given judgment on the appeals of the European Commission, GSK and two trade associations against the judgment of the European Court of First Instance ("ECFI") in the GSK dual pricing parallel exports case, Joined Cases C-50106P, C-51506P and C-51906P, GlaxoSmithKline Services Unlimited, formerly Glaxo Wellcome plc v Commission and Commission, EAEPC and Aseprofar v GlaxoSmithKline Services Unlimited, formerly Glaxo Wellcome plc

Pfizer’s arrangements with Unichem

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • October 30 2007

The High Court dismissed an application for an interim injunction by AAH Pharmaceuticals Limited and seven other pharmaceutical wholesalers to restrain the implementation of Pfizer Limited’s new single “direct to pharmacy” distribution arrangements for its prescription drugs in the UK

Safe for now

  • Bird & Bird
  • -
  • United Kingdom, USA
  • -
  • March 12 2008

In this article, Jeremy Robinson, Senior Associate in Bird & Bird’s International Competition Group, considers how the fight against cartels will be affected by today’s rulings in the House of Lords

The omission of notice implies misleading advertising

  • Bird & Bird
  • -
  • Italy
  • -
  • February 9 2011

It is also worth quoting a recent decision concerning misleading advertising in the field of food law

European General Court upholds findings of abuse of dominant position by AstraZeneca for misusing the SPC and marketing authorising systems

  • Bird & Bird
  • -
  • European Union
  • -
  • July 28 2010

The European General Court issued its judgment on 1 July 2010 on AstraZeneca's appeal against the European Commission's decision adopted on 15 June 2005 fining AstraZeneca ("AZ") EUR 60 million for abuse of dominant position through misuse of the patent system to obtain supplementary protection certificates (SPCs) and misuse of the pharmaceutical regulatory system by selective withdrawal of certain marketing authorisations

SFO’s price fixing prosecution of pharmaceutical companies rejected

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • December 31 2008

A prosecution brought by the Serious Fraud Office (“SFO”) alleging that a number of pharmaceutical companies had conspired to defraud the NHS of £120m by fixing the prices of various drugs has been abandoned after the Court of Appeal refused the SFO permission to appeal

Advocate General’s opinion supporting parallel trade in Greek case against GSK

  • Bird & Bird
  • -
  • European Union, Greece
  • -
  • May 7 2008

The long running saga of disputes between Greek exporter wholesalers and GSK following GSK’s refusal of supplies for export purposes has taken a new turn

Opinion of the Advocate General in the GSK dual pricing case pending before the European Court of Justice

  • Bird & Bird
  • -
  • European Union
  • -
  • July 17 2009

Advocate General Trstenjak has delivered her opinion on the appeals of the European Commission, GSK and two trade associations against the judgment of the European Court of First Instance ("ECFI") in the GSK dual pricing parallel exports case, Joined Cases C- 50106P, C-51506P and C-51906P, GlaxoSmithKline Services Unlimited, formerly Glaxo Wellcome plc v Commission and Commission, EAEPC and Aseprofar v GlaxoSmithKline Services Unlimited, formerly Glaxo Wellcome plc

Parallel trade in medicines: ECJ judgment in the second reference re: GlaxoSmithKline’s supply policy in Greece and abuse of dominant position

  • Bird & Bird
  • -
  • European Union, Greece
  • -
  • October 16 2008

In the second reference to the European Court of Justice arising out of GSK’s policy of selling medicines directly to Greek hospitals and pharmacies the ECJ has held (Joined Cases C-46806 to C-47806 Sot. Lelos kai Sia and Others) that an undertaking which occupies a dominant position on the relevant market for medicinal products is abusing its dominant position contrary to Article 82 EC if, in order to stop parallel exports, it refuses to meet “ordinary orders” from wholesalers